Processa Pharmaceuticals Inc (PCSA) concluded trading on Thursday at a closing price of $0.65, with 4.06 million shares of worth about $2.64 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -71.28% during that period and on January 30, 2025 the price saw a gain of about 10.57%. Currently the company’s common shares owned by public are about 3.71M shares, out of which, 3.34M shares are available for trading.
Stock saw a price change of -10.29% in past 5 days and over the past one month there was a price change of -28.03%. Year-to-date (YTD), PCSA shares are showing a performance of -25.90% which decreased to -76.44% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.47 but also hit the highest price of $3.31 during that period. The average intraday trading volume for Processa Pharmaceuticals Inc shares is 387.55K. The stock is currently trading -17.37% below its 20-day simple moving average (SMA20), while that difference is down -29.14% for SMA50 and it goes to -54.51% lower than SMA200.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) currently have 3.71M outstanding shares and institutions hold larger chunk of about 1.58% of that.
The stock has a current market capitalization of $2.43M and its 3Y-monthly beta is at 0.55. It has posted earnings per share of -$5.02 in the same period. It has Quick Ratio of 3.97 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PCSA, volatility over the week remained 20.15% while standing at 11.88% over the month.
Stock’s fiscal year EPS is expected to rise by 52.24% while it is estimated to increase by 46.67% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on April 25, 2024 offering a Buy rating for the stock and assigned a target price of $8 to it.
